S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NYSE:NVO

Novo Nordisk A/S Stock Forecast, Price & News

$69.61
+0.39 (+0.56 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$67.92
Now: $69.61
$69.78
50-Day Range
$69.22
MA: $72.36
$75.82
52-Week Range
$49.24
Now: $69.61
$75.86
Volume1.32 million shs
Average Volume1.13 million shs
Market Capitalization$163.92 billion
P/E Ratio26.17
Dividend Yield1.06%
Beta0.46
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S logo

Headlines

Diabetes drug hailed as a breakthrough for weight loss
February 11, 2021 |  finance.yahoo.com
Novo Nordisk A/S (NVO) Q4 2020 Earnings Call Transcript
February 3, 2021 |  finance.yahoo.com
Novo Nordisk A/S to Host Earnings Call
February 3, 2021 |  finance.yahoo.com
Novo Nordisk's net profit increased by 8% in 2020
February 3, 2021 |  finance.yahoo.com
Is NVO A Good Stock To Buy?
December 19, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888
Employees44,326
Year Founded1923

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.30 billion
Cash Flow$2.77 per share
Book Value$3.65 per share

Profitability

Net Income$5.84 billion

Miscellaneous

Outstanding Shares2,354,800,000
Market Cap$163.92 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.34 out of 5 stars

Medical Sector

715th out of 1,968 stocks

Pharmaceutical Preparations Industry

345th out of 771 stocks

Analyst Opinion: 1.1Community Rank: 2.1Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
$69.61
+0.39 (+0.56 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

Is Novo Nordisk A/S a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Novo Nordisk A/S?

Wall Street analysts have given Novo Nordisk A/S a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novo Nordisk A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Novo Nordisk A/S
.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings results on Tuesday, February, 2nd. The company reported $4.01 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.60 by $3.41. Novo Nordisk A/S had a net margin of 32.65% and a trailing twelve-month return on equity of 71.46%.
View Novo Nordisk A/S's earnings history
.

How has Novo Nordisk A/S's stock been impacted by Coronavirus?

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVO stock has increased by 20.2% and is now trading at $69.61.
View which stocks have been most impacted by COVID-19
.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a semi-annual dividend on Tuesday, February 23rd. Shareholders of record on Monday, March 29th will be given a dividend of $0.9494 per share on Wednesday, April 7th. This represents a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, March 26th. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.78.
View Novo Nordisk A/S's dividend history
.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S pays an annual dividend of $0.74 per share and currently has a dividend yield of 1.06%. Novo Nordisk A/S does not yet have a strock track record of dividend growth. The dividend payout ratio of Novo Nordisk A/S is 30.08%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 25.00% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S updated its FY 2021 Pre-Market earnings guidance on Wednesday, February, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $21.354-22.167 billion, compared to the consensus revenue estimate of $21.76 billion.

What price target have analysts set for NVO?

10 Wall Street analysts have issued 1-year price targets for Novo Nordisk A/S's stock. Their forecasts range from $72.00 to $72.00. On average, they expect Novo Nordisk A/S's stock price to reach $72.00 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts' price targets for Novo Nordisk A/S
or view top-rated stocks among Wall Street analysts.

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the following people:
  • Mr. Lars Fruergaard Jørgensen, Pres, CEO & Member of Management Board (Age 55) (LinkedIn Profile)
  • Mr. Karsten Munk Knudsen, Exec. VP, CFO & Member of the Management Board (Age 50) (LinkedIn Profile)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP, Chief Scientific Officer, Head of R&D and Member of the Management Board (Age 61) (LinkedIn Profile)
  • Mr. Henrik Ehlers Wulff, Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board (Age 51) (LinkedIn Profile)
  • Ms. Camilla Sylvest, Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board (Age 49) (LinkedIn Profile)
  • Ms. Monique Carter, Exec. VP, Head of People & Organisation and Member of Management Board (Age 48) (LinkedIn Profile)
  • Mr. Maziar Mike Doustdar, Exec. VP, Head of International Operations & Member of the Management Board (Age 51) (LinkedIn Profile)
  • Mr. Douglas J. Langa, Exec. VP, Head of North America Operations & Member of Management Board (Age 55) (LinkedIn Profile)
  • Mr. Ludovic Helfgott, Exec. VP, Head of Biopharm & Member of Management Board (Age 47) (LinkedIn Profile)
  • Mr. Peter Hugreffe Ankersen, Head of Investor Relations & Corp. VP

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.14%), Fisher Asset Management LLC (0.67%), Folketrygdfondet (0.24%), Fayez Sarofim & Co (0.21%), Everett Harris & Co. CA (0.14%) and Clearbridge Investments LLC (0.11%).
View institutional ownership trends for Novo Nordisk A/S
.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Eaton Vance Management, Eaton Vance Management, Jennison Associates LLC, Credit Suisse AG, BlackRock Inc., Alliancebernstein L.P., and Calamos Advisors LLC.
View insider buying and selling activity for Novo Nordisk A/S
or view top insider-selling stocks.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Amundi Pioneer Asset Management Inc., Clearbridge Investments LLC, Folketrygdfondet, Fisher Asset Management LLC, Aperio Group LLC, Creative Planning, and Penbrook Management LLC.
View insider buying and selling activity for Novo Nordisk A/S
or or view top insider-buying stocks.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $69.61.

How much money does Novo Nordisk A/S make?

Novo Nordisk A/S has a market capitalization of $163.92 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis.

How many employees does Novo Nordisk A/S have?

Novo Nordisk A/S employs 44,326 workers across the globe.

Does Novo Nordisk A/S have any subsidiaries?

The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., Calibrium, Churchill Stateside Solar Fund XIV LLC, Corvidia, Emisphere Technologies, MB2 LLC, NNE A/S, Novo Investment Pte Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk B.V., Novo Nordisk Biopharm Limited, Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comercio Produtos Farmaceuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungaria Kft., Novo Nordisk Inc., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZ-LLC, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Scandinavia AB, Novo Nordisk Scandinavia AS, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representacion C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, and Ziylo.

When was Novo Nordisk A/S founded?

Novo Nordisk A/S was founded in 1923.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is www.novonordisk.com.

Where are Novo Nordisk A/S's headquarters?

Novo Nordisk A/S is headquartered at Novo Alle, Bagsvaerd G7, 2880.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.